EUCTR2005-001459-39-IT进行中（未招募）不适用
Efficacy of mesalazine in the long term prevention of diverticulitis relapses.Randomised study, double blind, controlled vs placebo.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- SOFAR SPA
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
已完成
3 期
Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis FlaresDiverticular DiseaseNCT01120340SOFAR S.p.A.105
已完成
2 期
Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomassporadic colorectal adenomasporadic colorectal adenomatous polyps1001793410017987NL-OMON38274niversitair Medisch Centrum Utrecht68
进行中（未招募）
不适用
Mesalazine for the prevention of colorectal cancer: effects in patients with a history of sporadic adenomatous polypsEUCTR2011-001815-29-NLMC Utrecht
进行中（未招募）
1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136